Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Herbst

Showing results (31-40 of 395) with videos related to

Pageof 40
Sort By:
American Journal of Mental Deficiency|March 1, 1983
Nonspecific mental retardation in British Columbia as ascertained through a registryD S Herbst, P A Baird
The Oncologist|June 5, 2004
Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?Roy S Herbst, Alan B Sandler
Clinical Lung Cancer|May 1, 2004
Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical dataRalph G Zinner, Roy S Herbst
Methods of Information in Medicine|August 7, 2009
The human ecology of malaria in a highland region of South-West KenyaSophia Githinji, S Herbst, T Kistemann
Clinical Lung Cancer|January 11, 2005
Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancerRoy S Herbst, Alan B Sandler
Clinical Lung Cancer|November 20, 2003
Integration of targeted therapies in gemcitabine chemotherapy regimensGeorge R Blumenschein, Roy S Herbst
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Targeting the epidermal growth factor receptor in non-small cell lung cancerRoy S Herbst, Paul A Bunn
Seminars in Oncology|March 15, 2002
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancersRoy S Herbst, Corey J Langer
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Gefitinib: current and future status in cancer therapyRoy S Herbst, Merrill S Kies
Clinical Laboratory Management Review : Official Publication of the Clinical Laboratory Management Association|August 6, 1995
A model to begin reengineering the laboratory. How do you change an outmoded laboratory structure?D S Herbst, J E Dimmick
Pageof 40

Showing results (31-40 of 395) with videos related to

Sort By:
Pageof 40
American Journal of Mental Deficiency|March 1, 1983
Nonspecific mental retardation in British Columbia as ascertained through a registryD S Herbst, P A Baird
The Oncologist|June 5, 2004
Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?Roy S Herbst, Alan B Sandler
Clinical Lung Cancer|May 1, 2004
Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical dataRalph G Zinner, Roy S Herbst
Methods of Information in Medicine|August 7, 2009
The human ecology of malaria in a highland region of South-West KenyaSophia Githinji, S Herbst, T Kistemann
Clinical Lung Cancer|January 11, 2005
Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancerRoy S Herbst, Alan B Sandler
Clinical Lung Cancer|November 20, 2003
Integration of targeted therapies in gemcitabine chemotherapy regimensGeorge R Blumenschein, Roy S Herbst
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Targeting the epidermal growth factor receptor in non-small cell lung cancerRoy S Herbst, Paul A Bunn
Seminars in Oncology|March 15, 2002
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancersRoy S Herbst, Corey J Langer
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Gefitinib: current and future status in cancer therapyRoy S Herbst, Merrill S Kies
Clinical Laboratory Management Review : Official Publication of the Clinical Laboratory Management Association|August 6, 1995
A model to begin reengineering the laboratory. How do you change an outmoded laboratory structure?D S Herbst, J E Dimmick
Pageof 40